Company news
MoonLake Immunotherapeutics news in 2022
MoonLake Immunotherapeutics's news releases, calls and decks from 2022, newest first.
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
December 13, 2022
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
November 13, 2022
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
September 25, 2022
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
July 25, 2022
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 11, 2022
Decks in 2022
- Investor Day (June 2022)
Investor day · 77 slides · Jun 7, 2022
- Helix Acquisition — SPAC Merger (January 2022)
SPAC merger · 33 slides · Jan 19, 2022